On September 30, 2024, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of Adial Pharmaceuticals, Inc. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 336,310 shares of Adial Pharmaceuticals, which represents 4.99% of the company's class of common stock. The filing was made under Rule 13d-1(b), which applies to certain institutional investment managers. The shares are held by the Master Fund, which is managed by Armistice Capital, and Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The filing also certifies that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.

On September 30, 2024, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of Adial Pharmaceuticals, Inc. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 336,310 shares of Adial Pharmaceuticals, which represents 4.99% of the company's class of common stock. The filing was made under Rule 13d-1(b), which applies to certain institutional investment managers. The shares are held by the Master Fund, which is managed by Armistice Capital, and Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The filing also certifies that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.